Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial

Am J Dis Child. 1991 Dec;145(12):1401-4. doi: 10.1001/archpedi.1991.02160120069022.

Abstract

Patients with cystic fibrosis may still have a significant degree of steatorrhea despite adequate pancreatic enzyme supplementation. Taurine is a conditionally essential amino acid that possibly improves the micellar phase of fat digestion. Thirteen children with cystic fibrosis and a significant degree of steatorrhea (> 13 g/d) were enrolled in a randomized double-blind crossover study of taurine (30 mg/kg per day) in contrast to placebo for two successive 4-month periods. No difference was noted in height and weight velocity, lung function, vitamin A level, and essential fatty acid status. Twelve of the 13 patients showed a decrease in fecal fatty acid excretion (26.5 +/- 2.6 g/24 h vs 15.4 +/- 2.5 g/24 h), affecting mainly saturates and monounsaturates, and a decrease in total sterol excretion (1492.6 +/- 303 mg/24 h vs 1211.7 +/- 213.8 mg/24 h) while ingesting taurine. Taurine may be a useful adjunct in patients with cystic fibrosis and severe steatorrhea.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Body Height
  • Body Weight
  • Celiac Disease / blood
  • Celiac Disease / drug therapy*
  • Celiac Disease / etiology
  • Celiac Disease / physiopathology
  • Child
  • Cystic Fibrosis / complications*
  • Double-Blind Method
  • Fatty Acids / analysis
  • Feces / chemistry
  • Female
  • Forced Expiratory Flow Rates
  • Humans
  • Male
  • Nutritional Status
  • Sterols / analysis
  • Taurine / pharmacology
  • Taurine / therapeutic use*
  • Vital Capacity
  • Vitamin A / blood

Substances

  • Fatty Acids
  • Sterols
  • Vitamin A
  • Taurine